XSHE000915
Market cap825mUSD
Jan 10, Last price
25.83CNY
1D
-3.73%
1Q
-14.47%
Jan 2017
-20.30%
Name
Shandong WIT Dyne Health Co Ltd
Chart & Performance
Profile
Shandong Shanda Wit Science and Technology Co., Ltd. engages in the pharmaceutical and environment protection businesses in China. Its medical products include azithromycin granules, glycyrrhiza zinc granules, compound calcium carbonate, vitamin AD drops, epalrestat tablets, valsartan hydrochlorothiazide gums, roxithromycin, rosiglitazone tartrate tablets, and glimepiride tablets. The company offers environmental products, including deep disc filters, sulfuric acid diluents, industrial wastewater treatment solutions, chlorine dioxide generators, chlorine dioxide purifiers, and flue gas desulfurization and denitrification emission technology, as well as plans and constructs artificial wetland. Its environmental products also comprise optional equipment and raw materials; chlorine dioxide disinfectants, compounds, and composites; waste gas treatment; and solid waste treatment. The company also provides information products, such as DLP splicing display units, LCD splicing display units, image stitching processors, industrial automation control products, and communication products; and crystal products. In addition, it is involved in the provision of education services. The company was founded in 1993 and is based in Jinan, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 2,484,166 6.11% | 2,341,076 15.49% | |||||||
Cost of revenue | 861,995 | 1,072,848 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 1,622,170 | 1,268,227 | |||||||
NOPBT Margin | 65.30% | 54.17% | |||||||
Operating Taxes | 198,304 | 161,304 | |||||||
Tax Rate | 12.22% | 12.72% | |||||||
NOPAT | 1,423,866 | 1,106,923 | |||||||
Net income | 585,262 -41.35% | 997,889 41.69% | |||||||
Dividends | (690,884) | ||||||||
Dividend yield | 10.19% | ||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
Debt | |||||||||
Debt current | 7,892 | ||||||||
Long-term debt | |||||||||
Deferred revenue | 68,565 | ||||||||
Other long-term liabilities | 77,857 | 1 | |||||||
Net debt | (3,610,090) | (2,785,629) | |||||||
Cash flow | |||||||||
Cash from operating activities | 1,174,685 | 1,196,405 | |||||||
CAPEX | (50,611) | ||||||||
Cash from investing activities | (181,296) | ||||||||
Cash from financing activities | (696,675) | ||||||||
FCF | 1,423,085 | 1,100,560 | |||||||
Balance | |||||||||
Cash | 3,262,091 | 2,793,521 | |||||||
Long term investments | 347,999 | ||||||||
Excess cash | 3,485,881 | 2,676,468 | |||||||
Stockholders' equity | 4,469,927 | 4,034,750 | |||||||
Invested Capital | 1,088,618 | 1,420,269 | |||||||
ROIC | 113.51% | 73.06% | |||||||
ROCE | 35.22% | 30.79% | |||||||
EV | |||||||||
Common stock shares outstanding | 234,105 | 234,331 | |||||||
Price | 28.96 -36.35% | 45.50 49.38% | |||||||
Market cap | 6,779,676 -36.41% | 10,662,083 49.38% | |||||||
EV | 4,684,344 | 9,353,831 | |||||||
EBITDA | 1,699,321 | 1,336,636 | |||||||
EV/EBITDA | 2.76 | 7.00 | |||||||
Interest | 580 | 225 | |||||||
Interest/NOPBT | 0.04% | 0.02% |